Review article

The genetics of hypertrophic cardiomyopathy

Mohammed Akhtar*, Perry Elliott

ABSTRACT

Hypertrophic cardiomyopathy (HCM) is most commonly transmitted as an autosomal dominant trait, caused by mutations in genes encoding cardiac sarcomere proteins\(^1\). Other inheritable causes of the disease include mutations in genes coding for proteins important in calcium handling or that form part of the cytoskeleton\(^4\)\(^-\)\(^6\). At present, the primary clinical role of genetic testing in HCM is to facilitate familial screening to allow the identification of individuals at risk of developing the disease\(^7\)\(^,\)\(^8\). It is also used to diagnose genocopies, such as lysosomal\(^9\)\(^-\)\(^11\) and glycogen storage disease which have different treatment strategies, rates of disease progression and prognosis\(^12\)\(^-\)\(^14\). The role of genetic testing in predicting prognosis is limited at present, but emerging data suggest that knowledge of the genetic basis of disease will assume an important role in disease stratification\(^15\)\(^-\)\(^17\) and offer potential targets for disease-modifying therapy in the near future\(^18\).

https://doi.org/10.21542/gcsp.2018.36

Received: 01 August 2018
Accepted: 12 August 2018

© 2018 The Author(s), licensee Magdi Yacoub Institute. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy, Global Cardiology Science and Practice 2018:36 https://doi.org/10.21542/gcsp.2018.36
GENETIC ARCHITECTURE OF HCM

Familial HCM is characterized by locus and allelic heterogeneity, with a high frequency of novel individual mutations. The first genetic mutation to be identified was a single base substitution in the MYH7 gene encoding β-myosin heavy chain, a key component of the cardiac sarcomere. Since then, many different mutations in MYH7 and other genes of the cardiac sarcomere have been identified. In 5–10% of cases, HCM is caused by mutations in genes that cause metabolic disorders, neuromuscular disease, or inherited genetic syndromes including Noonan syndrome (Figure 1).

THE CARDIAC SARCOMERE

Every cardiomyocyte is composed of myofibrils that run longitudinally along the cell and are transversely subdivided into contractile units called sarcomeres. The sarcomere constitutes the fundamental motor unit of the cardiomyocyte and is composed of two principal components—the thick filament composed of around 300 molecules of myosin, each made up of 2 protein units of β- or α-myosin heavy chain and 4 myosin light chain molecules, and the thin filament composed of repeating actin molecules, closely associated with the regulatory troponin complex (troponin T (TnT), troponin I (TnI))

![Diagram of the cardiac sarcomere](image)

Figure 1. Representation of the percentage of hypertrophic cardiomyopathy cases accounted for by pathogenic mutations in sarcomeric and non-sarcomere genes. Elliott PM, et al; 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), European Heart Journal 2014; 35 (39): 2733–2779, doi:10.1093/eurheartj/ehu284. Reproduced by permission of Oxford University Press on behalf of the European Society of Cardiology. (c) European Society of Cardiology 2014. All rights reserved. For permissions please email journals.permissions@oup.com. This figure is not included under the Open Access license of this publication.
and troponin C (TnC)) and α-tropomyosin. An additional protein, cardiac myosin-binding protein C, contributes to the regulation of actin–myosin interaction and cross-bridge kinetics (Figure 2).

Muscle contraction results from the interaction between myosin and actin in which the globular head of the myosin molecule bends towards and then binds to actin, contracts, releases actin, and then initiates a new cycle. The links between the myosin head and actin are called cross-bridges; the contraction of the myosin S1 region which requires the hydrolysis of ATP to release energy is called the power stroke. Electrical activation of the heart and cardiomyocyte contraction are coupled through the intracellular movement of calcium. Depolarisation of the cardiomyocyte cell membrane activates the L-type voltage-dependent calcium channels in the T tubule causing an influx of calcium into the cell that triggers opening of ryanodine-receptor channels in the adjacent sarcoplasmic reticulum with a rapid increase in cytosolic calcium. Calcium binds to TnC, inducing an allosteric conformational change in TnI and TnT that is transmitted to tropomyosin and exposes the myosin-binding sites of actin allowing the cross-bridges to form. The myosin heavy chain head, with ADP and inorganic phosphate bound to its nucleotide-binding pocket, then interacts with the exposed actin-binding sites followed by the release of ADP and inorganic phosphate, which occurs simultaneously with the power stroke. ATP then binds to the nucleotide-binding pocket of the myosin heavy chain head, which detaches from actin and myosin then hydrolyses ATP into ADP and inorganic phosphate restarting the contraction cycle.

Figure 2. Representation of the cardiac sarcomere with associated proteins and interactions. Reproduced from Ref. [31]. Abbreviations: TnI, Troponin I; TnC, Troponin C; TnT, Troponin T; Tm, Tropomyosin; c-MYBP-C, cardiac myosin binding protein-c; ELC, Essential Light Chain; RLC, Regulatory Chain; LMM, Light meromyosin. The domains of cMyBP-C are numbered from C0–C10; m is the regulatory motif between domains C1 and C2 and contains the PKA phosphorylation site; PA represents a proline / alanine-rich linker sequence between domains Co and C1.
SARCOMERE MUTATIONS IN HCM

Mutations in βMYH7 and MYBPC3 account for 60–70% of HCM patients with pathogenic variants\(^1\),\(^19\),\(^32\),\(^35\). Mutations in other sarcomere and associated protein genes are listed in Table 1. Mutations in MYH7 are predominantly missense, with single nucleotide-base substitutions resulting in a non-synonymous single amino acid substitution\(^20\),\(^36\). In contrast, the majority of mutations in MYBPC3 are nonsense mutations due to insertion/deletions, splice-site variants or frameshifts causing a premature stop codon that results in a truncated protein transcript\(^1\),\(^32\),\(^37\).

The majority of missense mutations are believed to have a dominant negative effect in which the mutant protein is incorporated into the sarcomere, but its interaction with the normal wild-type protein disrupts normal sarcomeric assembly and function (poison polypeptide hypothesis)\(^31\),\(^38\). Individual missense mutations may change an amino acid in a highly-conserved residue, alter important kinase domains (affecting ligand interaction) or change surface-exposed portion of a molecule altering protein-protein interaction. Missense mutations can also cause protein misfolding and accelerated degradation by ubiquitin-proteasomal surveillance pathways.

In truncating mutations, haploinsufficiency is thought to be the major disease mechanism\(^39\),\(^40\). The reported absence of detectable truncated myosin-binding protein C in western-blot analysis of myectomy specimens of patients with this mutation may be due to nonsense mediated mRNA decay of abnormal transcripts or ubiquitin-mediated proteasomal degradation of aberrant truncated protein\(^40\)–\(^43\).

Allelic heterogeneity can be partly explained by the effect of different mutations on the structure and function of the complete peptide. β-myosin heavy chain, for example, consists of a globular head, an α-helical rod and a hinge region. The globular head contains binding sites for ATPase and actin as well as interaction sites for regulatory and essential light chains in the head-rod region\(^31\). The majority of disease-causing β-myosin heavy chain mutations are found in one of four locations: the actin binding site, the nucleotide binding pocket, the hinge region adjacent to the binding site for two reactive thiols and in the α-helix close to the essential light chain interaction site\(^44\). Thus, different effects on protein function might be expected depending on the position of the mutation.

It has been speculated that the HCM disease phenotype results from reduced contractile function caused by altered actin-myosin interactions, and consequent inappropriate compensatory hypertrophic remodelling\(^45\),\(^46\). However, some MYH7 mutations are associated with increased cardiomyocyte mechanical contractile forces \textit{in vitro} and show an increase in calcium sensitivity, leading to increases in tension generation and ATPase activity. Animal and cell studies have also confirmed altered calcium homeostasis as a key contributor to the pathophysiological processes that lead to the development of LV hypertrophy\(^47\),\(^48\).

Troponin T mutations account for less than 5% of all cases of HCM but often show a particular phenotype. TNNT2 mouse models show varying degrees of myocyte disarray and fibrosis with minimal LVH, in common with TNNT2 disease expression in humans\(^49\),\(^50\). Troponin-mutated mice exhibit severely impaired myocardial relaxation, independent of the degree of fibrosis, and consistent with the finding of increased calcium sensitivity\(^51\)–\(^53\). Some studies suggest that some TNNT2 mutations are associated with a high incidence of sudden death which may also relate to calcium loading in cardiomyocytes\(^54\),\(^55\).

Findings from murine models of HCM suggest that the increased contractility seen with some mutations is at the expense of inefficient ATP utilization. Furthermore, animal
Table 1  List of genes in which pathogenic mutations are associated with hypertrophic cardiomyopathy. The chromosome location and the proportion of HCM cases attributed to mutations in these specific genes are included.

| Protein                      | Gene      | Chromosome location | Proportion of HCM caused by mutations |
|------------------------------|-----------|---------------------|---------------------------------------|
| **SARCOMERIC PROTEINS**     |           |                     |                                       |
| B-Myosin Heavy Chain 7       | MYH7      | 14q12               | 40–44%                                |
| Myosin-Binding Protein C 3   | MYBPC3    | 11p11               | 35–40%                                |
| Troponin T                   | TNNT2     | 1q32                | 5–15%                                 |
| Troponin I                   | TNNI3     | 19q13               | 5%                                    |
| Tropomyosin alpha-1 chain    | TPM1      | 15q22               | 3%                                    |
| Regulatory Myosin Light Chain| MYL2      | 12q24               | 1–2%                                  |
| Essential Myosin Light Chain| MYL3      | 3p21                | 1%                                    |
| Actin                        | ACTC1     | 15q14               | 1%                                    |
| Troponin C                   | TNNC1     | 3p21                | <1%                                   |
| **Z-DISK PROTEINS**          |           |                     |                                       |
| ZASP –LIM binding domain 3   | LBD3      | 10q22               | 1–5%                                  |
| Alpha-Actinin-2              | ACTN2     | 1q42                | <1%                                   |
| Ankyrin repeat domain containing protein –1 | ANKRD1 | 10q23 | <1% |
| Muscle LIM Protein           | CSRP3     | 11p15               | <1%                                   |
| Myozenin-2                   | MYOZ2     | 4q26                | <1%                                   |
| Telethonin                   | TCAP      | 17q12               | <1%                                   |
| Vinculin                     | VCL       | 10q22               | <1%                                   |
| Nexilin                      | NEXN      | 1p31                | <1%                                   |
| Filamin C                    | FLNC      | 7q32                | <1%                                   |
| **SARCOMERE-ASSOCIATED PROTEINS** | | | |
| Desmin                       | DES       | 2q35                | <1%                                   |
| Four and a Half Lim Domain Protein –1 | FHL-1 | Xq26 | <1% |
| **CALCIUM-HANDLING PROTEINS** |           |                     |                                       |
| Phospholamban                | PLN       | 6q22                | <1%                                   |
| Calreticulin 3               | CALR3     | 19p13               | <1%                                   |
| Calsequestrin 2              | CASQ2     | 1p13                | <1%                                   |
| Junctophilin 2               | JPH2      | 20q13               | <1%                                   |
| **HCM PHENOCOPIES (METABOLIC & LYSOSOMAL STORAGE DISORDERS)** | | | Together with other HCM phenocopies account for 5–10% of HCM cases |
| AMP-gamma2 subunit           | PRKAG2    | 7q36                |                                       |
| Glucosidase A (Pompe’s disease) | GAA | 17q25 |       |
| Alpha-Galactosidase A (Anderson-Fabry Disease) | GLA | Xq22 |       |
| Lysosomal-associated membrane protein 2 (Danon’s Syndrome) | LAMP2 | Xq24 |       |
| **HCM PHENOCOPIES (Ras-MAPK)** | | | Together with other HCM phenocopies account for 5–10% of HCM cases |
| Noonan Syndrome              | KRAS      | 12p12               |                                       |
|                             | SOS1      | 2p22                |                                       |
|                             | PTPN11    | 12q24               |                                       |
|                             | RAF1      | 3p25                |                                       |
| **LEOPARD syndrome**         | PTPN11    | 12q24               |                                       |
|                             | RAF1      | 3p25                |                                       |
| **HCM PHENOCOPY (NEUROMUSCULAR DISORDERS)** | | | Together with other HCM phenocopies account for 5–10% of HCM cases |
| Friedreich’s Ataxia          | GAA expansion in FXN | 9q13 |       |
and human studies suggest that HCM is associated with depleted energy stores and abnormal ATP/ADP ratios.\textsuperscript{56–59} Inefficient utilization of ATP is also seen in metabolic disorders or mitochondrial cytopathies, which can produce a pattern of LV hypertrophy similar to that in sarcomeric HCM.

Recently, mutations in genes encoding z-disc proteins including myozenin (MYOZ2), telethonin (TCAP), alpha-actinin-2 (ACTN2), muscle LIM protein (CRP3) and nexilin (NEXN) have been implicated in HCM.\textsuperscript{31} Some mutations in Z-disc proteins have a pleotropic effect, causing an HCM phenotype in certain individuals and a DCM phenotype in others within the same family.\textsuperscript{60}

**CHILDHOOD-ONSET HCM**

The importance of sarcomeric protein gene mutations in childhood hypertrophic cardiomyopathy is unknown. The observation that the development of left ventricular hypertrophy in individuals with familial disease often occurs during the period of somatic growth in adolescence has led to the suggestion that sarcomeric protein disease in very young children is rare.\textsuperscript{61,62} However, studies of children with HCM have shown that, as in adults, sarcomeric protein gene mutations account for approximately 50% of cases of idiopathic HCM, even in infants and young children.\textsuperscript{63,64}

**PHENOTYPIC VARIABILITY**

There is a substantial variation in the expression of identical mutations indicating that other genetic and possibly environmental factors influence disease expression. The effect of age is perhaps the best characterized factor, most patients developing ECG and echocardiographic manifestations of the disease after puberty and before the age of thirty.\textsuperscript{65,66} Sex also appears to influence disease expression in sarcomere protein disease.\textsuperscript{67,68} Other potential modifying factors include renin-angiotensin-aldosterone system gene polymorphism,\textsuperscript{69–71} and the occurrence of homozygosity and compound heterozygosity.\textsuperscript{72–74}

**GENETIC ADVANCEMENTS**

The impact of more rapid, cost-effective gene sequencing methods, together with improved cellular models including induced pluripotent stem cells, gene-editing technology, larger sequenced control cohorts and deep clinical phenotyping in cases means that we are at an exciting crossroads in the genetics of HCM. This provides researchers with significant opportunity to identify novel candidate causative genes and to potentially allow clearer genotype-phenotype correlations to be made, thereby laying the foundation for more personalised patient care.

**REFERENCES**

[1] Richard P, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227–32.

[2] Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99(24):1800–11.

[3] Erdmann J, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64(4):339–49.

[4] Landstrom AP, et al. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am Heart J. 2011;161(1):165–71.
[5] Landstrom AP, et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol. 2007;42(6):1026–35.

[6] Landstrom AP, Ackerman MJ. Beyond the cardiac myofilament: hypertrophic cardiomyopathy-associated mutations in genes that encode calcium-handling proteins. Curr Mol Med. 2012;12(5):507–18.

[7] Charron P, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715–26.

[8] Authors/Task Force, m, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.

[9] Elliott P, et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011;97(23):1957–60.

[10] Sachdev B, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407–11.

[11] Kawas RF, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292(40):16571–16577.

[12] Weidemann F, et al. The cardiomyopathy in Friedreich’s ataxia - New biomarker for staging cardiac involvement. Mayo Clin Proc. 2008;83(6):630–8.

[13] van Velzen HG, et al. Value of Genetic Testing for the Prediction of Long-Term Outcome in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(6):881–887.

[14] Kawas RF, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292(40):16571–16577.

[15] Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–15.

[16] Lopes LR, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101(4):294–301.

[17] Olivoto I, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83(6):630–8.

[18] Lee DH, et al. Hypertrophic cardiomyopathy in Pompe disease is not limited to the classic infantile-onset phenotype. JIMD Rep. 2014;17:71–5.

[19] Rosmini S, et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart. 2017;103(4):300–306.

[20] Lopes LR, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in patients with hypertrophic cardiomyopathy. Circ Res. 2005;96(6):922–30.

[21] MacRae CA, et al. Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest. 1995;96(3):1216–20.

[22] Gollob MH, et al. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol. 2002;17(3):229–34.

[23] Filla A, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59(3):554–60.

[24] Weidemann F, et al. The cardiomyopathy in Friedreich’s ataxia - New biomarker for staging cardiac involvement. Int J Cardiol. 2015;194:50–7.

[25] Weidemann F, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation. 2012;125(13):1626–34.

[26] Hickey EJ, et al. Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. Mayo Clin Proc. 2015;90(8):842–6.

[27] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[28] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[29] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[30] Moore JR, Leinwand L, Warshaw DM. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res. 2012;111(3):375–85.

[31] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[32] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[33] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[34] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[35] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[36] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.

[37] Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751–64.
[37] Carrier L, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res. 1997;80(3):427–34.

[38] Keren A, Syriss P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5(3):158–68.

[39] Bae residue, et al. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J Mol Cell Cardiol. 2015;79:234–43.

[40] Marston S, et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009;105(3):219–22.

[41] Carrier L, et al. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res. 2010;85(2):330–8.

[42] Sarikas A, et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res. 2005;66(1):33–44.

[43] van Dijk SI, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119(11):1473–83.

[44] Woo A, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart. 2003;89(10):1179–85.

[45] Yang Q, et al. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res. 1999;85(9):S41–7.

[46] Razumova MV, et al. Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay: Evidence for long lived cross bridges. J Biol Chem. 2006;281(47):35846–54.

[47] Lan F, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101–13.

[48] Guinto PJ, et al. Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol. 2009;297(2):H614–26.

[49] Pasquale F, et al. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ Cardiovasc Genet. 2012;5(1):10–7.

[50] Ferrantini C, et al. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. J Am Heart Assoc. 2017;6(7).

[51] Lombardi R, et al. Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res. 2008;79(1):109–17.

[52] Maas AH, et al. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T. Circulation. 2004;110(15):2102–9.

[53] Tardiff JC, et al. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest. 1999;104(4):469–81.

[54] Watkins H, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058–64.

[55] Gimeno JR, et al. Hypertrophic cardiomyopathy. A study of the troponin-T gene in 127 Spanish families. Rev Esp Cardiol. 2009;62(12):1473–7.

[56] Palmer BM, et al. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol. 2004;287(1):H91–9.

[57] Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res. 1999;44(1):20–36.

[58] Spindler M, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of hypertrophic cardiomyopathy. J Biol Chem. 2006;281(47):35846–54.

[59] Tyska MJ, et al. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of hypertrophic cardiomyopathy. Circ Res. 2000;86(7):737–44.

[60] Bos JM, Ackerman MJ. Z-disc genes in hypertrophic cardiomyopathy: stretching the cardiomyopathies? J Am Coll Cardiol. 2010;55(11):1136–8.

[61] Colan SD, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115(6):773–81.

[62] Nugent AW, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation. 2005;112(9):1332–8.

[63] Rupp S, et al. Genetic basis of hypertrophic cardiomyopathy in children. Clin Res Cardiol. 2018.

[64] Kaski JP, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2(5):436–41.

[65] Michels M, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009;30(21):2593–8.

[66] Charron P, et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns. 1997;8(2):107–14.

[67] Olivotto I, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(5):480–7.

[68] Geske JB, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38(6):3434–3440.

[69] Kaufman BD, et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet. 2007;122(5):515–23.
[70] Perkins MJ, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. *Eur Heart J*. 2005;26(22):2457–62.

[71] Ortlepp JR, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. *Heart*. 2002;87(3):270–5.

[72] Zhou N, et al. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. *Eur J Med Genet*. 2018.

[73] Marziliano N, et al. A case of compound mutations in the MYBPC3 gene associated with biventricular hypertrophy and neonatal death. *Neonatology*. 2012;102(4):254–8.

[74] Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. *Heart Rhythm*. 2012;9(1):57–63.